StockData

Rocket One Inc. (RKTO) company profile

RKTONasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 13, 2026Score 6/30
$0.30−0.01 (-4.64%)

Close on Nov 18, 2026Market cap $7.53MP/E –Yield –

About Rocket One

Pharmaceutical Preparations, SIC 2834

Hoth Therapeutics, Inc. is a clinical-stage biopharmaceutical company that develops new generation therapies designed to address unmet medical needs. The company's development pipeline features drug candidates targeting various conditions across oncology, dermatology, allergy, and neurology. Key pipeline assets include HT-001, a topical formulation for treating skin toxicities resulting from cancer therapies; HT-KIT, a targeted therapeutic for mast cell-derived neoplasms and anaphylaxis; and HT-ALZ, an asset aimed at treating and preventing Alzheimer’s disease and other neuroinflammatory conditions. Additional programs comprise BioLexa for atopic dermatitis, HT-004 for asthma and allergies, and HT-VA for obesity. The company creates these therapies primarily for patients requiring specialized interventions.

The company operates in the United States and has conducted clinical activities in Australia, while securing regulatory authorizations to expand trials into European nations including Spain, Poland, and Hungary. Hoth Therapeutics maintains its principal executive offices in Hoboken, New Jersey.

Summary of the business section of Rocket One's latest annual report, written by StockData.

Company profile

Company

Legal name
Rocket One Inc.
Founded
2017
Headquarters
Hoboken, NJ
Address
720 Monroe Street, Suite E514 07030
Phone
(866) 239-7459
Employees
2, Dec 31, 2025
Industry
Pharmaceutical Preparations
Incorporated in
Nevada
Fiscal year ends
December 31
Auditor
WithumSmith+Brown, PC, East Brunswick, New Jersey

Stock & identifiers

Ticker
RKTO
Former tickers
HOTH until May 27, 2026
Exchange
Nasdaq
IPO date
Feb 15, 2019
Shares outstanding
25M, Aug 14, 2026
Public float
$15.40M, Jun 30, 2025
Filer category
Non-accelerated filer<br>Smaller reporting company
Stock splits
1-for-25 reverse, Oct 26, 2022
SEC CIK
1711786
CUSIP
44148G204
ISIN
US44148G2049
FIGI
BBG00H0HZ8S8
Share class FIGI
BBG00H0HZ8T7
EIN
82-1553794

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Robb KnieCEO and President, Director547,387
David SarnoffDirector25,000
Wayne LinsleyDirector3,333
Jeff PavellDirector5,075
Christopher Michael CamarraDirector–
Graig SpringerDirector3,333

CEO pay and shareholder return

Pay versus performance table from the proxy statement

Fiscal yearCEO total payCEO pay actually paidOther executives (avg)Value of $100 investedPeer group
FY2025$1.93M$1.93M–$2–
FY2024$1.23M$1.23M–$1–
FY2023$846.34K$846.34K–$2–
FY2022$1.06M$1.06M–$13–

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

Executive compensation, fiscal 2024

Summary compensation table from the latest proxy statement

ExecutiveSalaryBonusOption awardsOtherTotalvs. prior year
Robb Knie
Chief Executive Officer and President
$450.00K$200.00K$449.69K$127.11K$1.23M+45%

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

IPO

From the final prospectus (Form 424B4) and the first day of trading

Offering

Type
Initial public offering
Final prospectus filed
Feb 15, 2019
Offer price
$5.60
Securities offered
1,250,000
Gross proceeds
$7.00M
Exchange
Nasdaq
First trading day
Feb 15, 2019
First-day close
$8.53+52.3%
Lock-up ends (est.)
Aug 14, 2019

“Per Share Total Initial public offering price $ 5.60 $ 7,000,000 Underwriting discounts and commissions(1)(2) $ 0.392 $ 490,000 Proceeds to us, before expenses $ 5.208 $ 6,510,000 (1) We refer you to “Underwriting (Conflicts of Interest)” beginning on page 89 of this prospectus for additional information regarding”

Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.

Employees

Headcount reported in annual reports

“As of March 26, 2025, we employed a total of 2 full-time employees, 3 employee consultants, and 1 part-time employee.”

Corporate history

Events identified from SEC filings

See a number that looks wrong?